Effect of oral clodronate on metastatic bone pain: A double-blind, placebo-controlled study

Journal of Clinical Oncology

Volumn 13, Issue 9, 1995, Pages 2427-2430

  Robertson, A G ^b   Reed, N S ^b   Ralston, S H ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANALGESIC AGENT; CLODRONIC ACID; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; GESTAGEN; LORON; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MYELOMA; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0029166436     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.9.2427     Document Type: Article

References (15)

1. Kanis JA, McCloskey EV: The use of clodronate in disorders of calcium and skeletal metabolism, in Kanis JA (ed): Calcium Metabolism: Progress in Basic and Clinical Pharmacology. Basel, Switzerland, Karger, 1990, pp 89-136
2. Elomaa I, Blomqvist C, Porkka L, et al: Long-term controlled trial with diphosphonate in patients with osteolytic metastases. Lancet 1:146-148, 1983
3. Elomaa I, Blomqvist C, Porkka L, et al: Diphosphonates for osteolytic metastases. Lancet 1:1156-1157, 1985
4. Paterson AHG, Powles TJ, Kanis JA, et al: Double blind placebo-controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993
5. van Holter-Verzantvoort AT, Bijvoet OLM, et al: Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 2:983-985, 1987
6. Lahtinen R, Laasko M, Palva I, et al: Randomised placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049-1052, 1992
7. Delmas PD, Charhon S, Chapuy MC, et al: Long-term effects of dichloromethylene diphosphonate on skeletal lesions in multiple myeloma. Metab Bone Dis Rel Res 4:163-168, 1982
8. Francini G, Gonelli S, Petroli R, et al: Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 10:591-598, 1992
9. Merlini G, Atterdo-Parrinello G, Piccinini L, et al: Long-term effects of parenteral dichloromethylene bisphosphonate on bone disease of myeloma patients treated with chemotherapy. Haematol Oncol 8:23-30, 1990
10. Adami S, Salvagno G, Guaerra G, et al: Dichloromethylene diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 134:1152-1154, 1985
11. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
12. Kylmala T, Tamella T, Ristelli L, et al: Evaluation of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish prostate cancer group. Eur J Cancer 29A:821-825, 1993
13. Compston JE: The therapeutic use of bisphosphonates. Br Med J 309:711-716, 1994
14. Botturi M, Zanni D, Tosi G: Disodium clodronate and radiotherapy in bone metastases from solid tumours. Radiol Med 80:726-733, 1990
15. Ernst DS, MacDonald RN, Paterson AHG, et al: A double blind crossover trial of intravenous clodronate in metastatic bone pain. J Pain Sympt Manag 7:4-11, 1992